Tracked deals
3
3 tracked deals across 2022-2024.
Public Company
Healthcare
AstraZeneca
Cambridge, Cambridgeshire, United Kingdom
A global, science-led biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines across therapy areas including Oncology and Respiratory & Immunology.
- Focus Areas
- Biopharmaceuticals, Prescription medicines, Oncology
- Website
- www.astrazeneca.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
3 buyout
AstraZeneca Acquisition Volume by Year
Last 3 years
Supporting Data
Recent Transactions
-
March 19, 2024
- Buyer
- AstraZeneca
- Target
- Fusion Pharmaceuticals Inc.
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.
-
December 12, 2023
- Buyer
- AstraZeneca
- Target
- Icosavax
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.
-
November 29, 2022
- Buyer
- AstraZeneca
- Target
- Neogene Therapeutics
- Seller
- Vida Ventures, TPG, EcoR1 Capital, Jeito Capital, Syncona, Polaris Partners, Pontifax, Two River Advisors, Arie Belldegrun
- Industry
- Biotechnology
- Location
- Netherlands
- Type
- Buyout
AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.
Related Acquisition Pages
Selling a company? Get in front of buyers like AstraZeneca
Turn tracked acquisition activity into an outreach-ready buyer list.